UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

# NOTICE OF ALLOWANCE AND FEE(S) DUE

5514 7590 12/31/2008 FITZPATRICK CELLA HARPER & SCINTO 30 ROCKEFELLER PLAZA

NEW YORK, NY 10112

EXAMINER

DANG, IAN D

ART UNIT PAPER NUMBER

DATE MAILED: 12/31/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,378	03/24/2006	Kenya Shitara	00005.01290.	4546

TITLE OF INVENTION: RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	03/31/2009

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and I/2 the ISSUE FFE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

### PART B - FEE(S) TRANSMITTAL

# Complete and send this form, together with applicable fee(s), to: Mail Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

appropriate. All further indicated unless corrects maintenance fee notifica	correspondence includir ed below or directed oth	ng the Patent, advance on herwise in Block 1, by (a	rders and notification of r a) specifying a new corres	naintenance fees w pondence address;	ill be and/o	mailed to the current (b) indicating a sepa	correspondence address as arate "FEE ADDRESS" for
	ENCE ADDRESS (Note: Use Bi	ock 1 for any change of address)	Note Feet pags have	e: A certificate of a s) Transmittal. This ers. Each additional to its own certificate	mailing s certil paper of ma	can only be used for icate cannot be used for such as an assignment ling or transmission.	or domestic mailings of the for any other accompanying int or formal drawing, must
5514	7590 12/31			Cert	ificate	of Mailing or Trans	mission
30 ROCKEFELI NEW YORK, N		ER & SCINTO	I he Stat addi tran	reby certify that thi es Postal Service w ressed to the Mail smitted to the USP	s Fee( ith sul Stop FO (57	s) Transmittal is being ficient postage for firs ISSUE FEE address I) 273-2885, on the d	g deposited with the United st class mail in an envelope above, or being facsimile ate indicated below.
							(Depositor's name)
			_				(Signature)
							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.
10/573,378	03/24/2006		Kenya Shitara			00005.01290.	4546
			MAN INSULIN-LIKE GR				
APPLN, TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	FEE	TOTAL FEE(S) DUE	
nonprovisional	NO	\$1510	\$300	\$0		\$1810	03/31/2009
EXAM		ART UNIT	CLASS-SUBCLASS				
DANG,		I647	530-387100				
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563).  Change of correspondence address (or Change of Correspondence Address form PTOVSB/122) attached.  "Fee Address" indication or "Fee Address" indication form PTOVSB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			2. For printing on the patent front page, list (1) the anness of up to 3 registered patent attorneys or agents OR, alternatively, (2) the names of a single firm (having as a member a registered autoracy or agent) and the names of up to 2 registered patent autoracys or agents. If no name is stied, no name wilb per printed.				
PLEASE NOTE: Uni recordation as set fort (A) NAME OF ASSI	less an assignee is ident h in 37 CFR 3.11. Comp GNEE		(B) RESIDENCE: (CITY	atent. If an assigne assignment. and STATE OR C	OUNT	'RY)	ocument has been filed for
			·		•		<del></del>
4a. The following fee(s)  Issue Fee	are submitted:	40	<ol> <li>Payment of Fee(s): (Plea</li></ol>	ise first reapply an	y prev	lously paid issue fee	shown above)
	vo small entity discount p	permitted)	Payment by credit car	d. Form PTO-2038	is atta	ched.	
Advance Order -	# of Copies		overpayment, to Depo	authorized to charge sit Account Numbe	ge the	required fee(s), any de enclose a	ficiency, or credit any n extra copy of this form).
	s SMALL ENTITY state	is. See 37 CFR I.27.	b. Applicant is no lon				
NOTE: The Issue Fee an interest as shown by the	d Publication Fee (if req records of the United Sta	uired) will not be accepted tes Patent and Trademark	d from anyone other than t Office.	he applicant; a regis	stered	attorney or agent; or th	ne assignee or other party in
Authorized Signature				Date			
Typed or printed nam			Registration N				
This collection of inform an application. Confiden submitting the complete this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223	nation is required by 37 C tiality is governed by 35 d application form to the ions for reducing this but 'irginia 22313-1450. DC k13-1450.	FR 1.311. The informatic U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the O NOT SEND FEES OR (	on is required to obtain or r 1.14. This collection is est depending upon the indiv e Chief Information Office COMPLETED FORMS TO	etain a benefit by the imated to take 12 m idual case. Any co- er, U.S. Patent and O THIS ADDRESS	ne pub ninute: mment Frader . SEN	lic which is to file (and to complete, including s on the amount of the lark Office, U.S. Dep D TO: Commissioner	d by the USPTO to process) g gathering, preparing, and me you require to complete artment of Commerce, P.O. for Patents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.



# UNITED STATES PATENT AND TRADEMARK OFFICE

#### UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

DATE MAILED: 12/31/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/573,378	03/24/2006	Kenya Shitara	00005.01290.	4546		
5514 7	590 12/31/2008		EXAMINER			
FITZPATRICK	CELLA HARPER &	DANG, IAN D				
30 ROCKEFELLER PLAZA			ART UNIT	PAPER NUMBER		
NEW YORK, NY	10112	1647				

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

# Application No. Applicant(s) 10/573,378 SHITARA ET AL Notice of Allowability Examiner Art Unit IAN DANG 1647 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. This communication is responsive to amendments filed 11/12/2008. 2. The allowed claim(s) is/are 1, 17-21, 25, 31-33, and 34 (renumbered as claims 1-11). 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) $\square$ All b) ☐ Some\* c) ☐ None of the: 1. T Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). \* Certified copies not received: \_\_\_\_\_. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. | Notice of References Cited (PTO-892) 5. Notice of Informal Patent Application 2. Notice of Draftperson's Patent Drawing Review (PTO-948) Interview Summary (PTO-413), Paper No./Mail Date Information Disclosure Statements (PTO/SB/08). 7. X Examiner's Amendment/Comment Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit 8. T Examiner's Statement of Reasons for Allowance of Biological Material Other .

Art Unit: 1647

# **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Lawrence Perry on Tuesday December 09, 2008.

The application has been amended as follows:

Cancel claims 26, 27, and 28,

In claim 1, line 7, after the word "sequence" delete "consisting".

In claim 1, line 8, after the word "sequence" delete "consisting".

In claim 17, line 3, after the word "sequence" delete "consisting".

In claim 18, line 3, after the word "sequence" delete "consisting".

In claim 19, line 3, after the word "sequence" delete "consisting".

antibody fragment thereof from the culture.—

In claim 25, line 2, after "1" delete "or" and insert --,--.

Add claim 32: insert –A process for producing a recombinant antibody or the antibody fragment thereof according to claim 20, which comprises a step of culturing a transformant obtained by introducing into a host cell an expression vector carrying DNA encoding said recombinant antibody or antibody fragment thereof in a medium to produce the recombinant antibody or the antibody fragment thereof in a culture, and isolating and purifying the recombinant antibody or the

Add claim 33: insert --A process for producing a recombinant antibody or the antibody fragment thereof according to claim 21, which comprises a step of culturing a transformant obtained by introducing into a host cell an expression vector carrying DNA encoding said recombinant antibody or antibody fragment thereof in a medium to produce the recombinant antibody or the antibody fragment thereof in a culture, and isolating and purifying the recombinant antibody or the antibody fragment thereof from the culture.—

Add claim 34: insert --A process for producing a recombinant antibody or the antibody fragment thereof according to claim 31, which comprises a step of culturing a transformant obtained by introducing into a host cell an expression vector carrying DNA encoding said recombinant antibody or antibody fragment thereof in a medium to produce the recombinant antibody or the antibody fragment thereof in a culture, and isolating and purifying the recombinant antibody or the antibody fragment thereof from the culture.—

### Election/Restrictions

Claims 1, 17, 18, 19, 20, 21, and 31 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claim 25, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 08/16/2007 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or

Application/Control Number: 10/573,378

Art Unit: 1647

divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to IAN DANG whose telephone number is (571)272-5014. The examiner can normally be reached on Monday-Friday from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

lan Dang Patent Examiner Art Unit 1647 December 12, 2008

> /Robert Landsman/ Primary Examiner, Art Unit 1647